| Names | |
|---|---|
| Preferred IUPAC name 4-(2,2-Dimethylpropanamido)butanoic acid | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider |
|
| ECHA InfoCard | 100.067.287 |
| EC Number |
|
| KEGG |
|
| MeSH | N-trimethylacetyl-4-aminobutyric+acid |
| UNII | |
| |
| |
| Properties | |
| C9H17NO3 | |
| Molar mass | 187.239 g·mol−1 |
| Pharmacology | |
| N06AX15 (WHO) | |
| Oral | |
| Pharmacokinetics: | |
| 6.4 hours | |
| Legal status |
|
| Related compounds | |
Related alkanoic acids | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Pivagabine (INN; brand nameTonerg), also known asN-pivaloyl-γ-aminobutyric acid orN-pivaloyl-GABA, is anantidepressant andanxiolyticdrug which was introduced inItaly in 1997 for the treatment ofdepressive andmaladaptivesyndromes. But it was discontinued in Italy (according toMartindale). Originally believed to function as aprodrug toGABA,[1] pivagabine is now believed to act somehow via modulation ofcorticotropin-releasing factor (CRF).[2][3][4][5][6]